Search Medical Condition
Please enter condition
Please choose location from dropdown

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (73) clinical trials

Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions

The role of vascular endothelial growth factor-C (VEGF-C) and its receptors induced lymphangiogenesis and host inflammatory responses on the carcinogenesis of oral cancers and premalignant lesions

Phase N/A

Expression of Hypoxia-Inducible Factor- in Oral Precancers and Cancers

Expression of hypoxia-inducible factor-α in oral precancers and cancers

Phase N/A

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The purpose of this study is to evaluate effectiveness ...

Phase

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

PHASE I: Participants will be enrolled sequentially and treated at Dose Level 1, or Dose Level -1, every 2 weeks for 12 cycles or until discontinuation. Each cycle is 4 weeks. Cetuximab is given alone in lead-in period at Day -14 before Cycle 1 only. In all subsequent doses starting ...

Phase

Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification HER2 Mutation/Amplification HER3/4 Mutation or KRAS Mutation

Objectives Primary Objectives: To evaluate the safety and tolerability of neratinib when combined with one of the following agents Arm 1: Everolimus (mTOR inhibitor) Arm 2: Palbociclib (CDK 4/6 inhibitor) Arm 3: Trametinib (MEK inhibitor) To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of neratinib combination therapy. ...

Phase

Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Objectives Primary Objectives: For Arms D-G, to establish the safety, tolerability, and dose-limiting toxicities (DLTs) of different treatment combinations of avelumab when administered in combination with checkpoint agonist(s) with or without radiation, or radiation and cisplatin in patients with limited, locally advanced or metastatic solid tumors in order to estimate ...

Phase

IACS-010759 in Advanced Cancers

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of IACS-010759, the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in subjects with any advanced solid tumor and lymphoma. SECONDARY OBJECTIVES: I. To evaluate IACS-010759 pharmacokinetics and preliminary antitumor activity (including overall response rate and duration of response). ...

Phase

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

PRIMARY OBJECTIVES: I. To determine whether 14-21 days of treatment with ACTOplus met XR will result in a decrease in proliferation index (Ki-67) expression in oral cavity/oropharyngeal tumor tissue as compared to placebo. SECONDARY OBJECTIVES: I. Compare differences in proliferation index (Ki-67) expression from baseline to post-exposure in visually normal ...

Phase

Patient Evaluation for Head and Neck Surgery Branch Studies

This protocol will provide a means for screening potential candidates for head and neck surgery branch protocols. No investigational treatments will be administered in this protocol. The PI may, however, approve a patient who has been determined to be ineligible for HNSB protocols to undergo standard treatment because they present ...

Phase N/A

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer

Phase